Bevacizumab is approved for use in recurrent glioblastoma, but whether it benefits patients with newly diagnosed glioblastoma remains unclear. Two new studies further question the use of the bevacizumab in this context, but leave much to be clarified about its optimal clinical application.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Taphoorn, M. J. et al. Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma. J. Clin. Oncol. 33, 2166–2175 (2015).
Kovic, B. & Xie, F. Economic evaluation of bevacizumab for the first-line treatment of newly diagnosed glioblastoma multiforme. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2014.59.7245.
Jain, R. K., Duda, D. G., Clark, J. W. & Loeffler, J. S. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3, 24–40 (2006).
Godard, S. et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 63, 6613–6625 (2003).
Stefanik, D. F. et al. Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft. J. Neurooncol. 55, 91–100 (2001).
Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733–4740 (2009).
Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740–745 (2009).
Chinot, O. L. et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722 (2014).
Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699–708 (2014).
Lou, E. et al. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma. Cancer Med. 2, 185–195 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author has served on advisory boards for Genentech.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Desjardins, A. What is the optimal use of bevacizumab in glioblastoma?. Nat Rev Neurol 11, 429–430 (2015). https://doi.org/10.1038/nrneurol.2015.127
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2015.127
This article is cited by
-
On glioblastoma and the search for a cure: where do we stand?
Cellular and Molecular Life Sciences (2017)
